Search results for " epiderma"

showing 10 items of 59 documents

Leaf and stem anatomy in eight Hypericum species (Clusiaceae).

2013

Abstract - Foliar micromorphology, epicuticular wax morphology and anatomical features of leaves and stem, particularly secondary xylem, were examined with light microscopy, general and histochemical staining and scanning electron microscopy in eight Hypericum species. Outer tegument tissue and type of secondary xylem are determining characteristics. Secondary xylem is ring-porous in H. perforatum, H. perfoliatum, H. tetrapterum, H. triquetrifolium, H. androsaemum and H. hircinum. In H. aegypticum and H. pubescens xylem is diffuse-porous, which is considered to be a more primitive type. These characteristics may be considered an additional criterion for species identification.

Hypericum speciesbiologyXylemClusiaceaePlant ScienceAnatomyViral tegumentbiology.organism_classificationAnatomy epiderma epicuticular wax Hypericum morphology SEM stem xylemHistochemical stainingepicuticular waxEpicuticular waxepidermaBotanymorphologySEMSpecies identificationxyemstemAnatomyHypericumEcology Evolution Behavior and SystematicsHypericumAnatomy; epiderma; epicuticular wax; Hypericum; morphology; SEM; stem; xylem
researchProduct

Topical Application of Glycolipids from Isochrysis galbana Prevents Epidermal Hyperplasia in Mice

2017

Chronic inflammatory skin diseases such as psoriasis have a significant impact on society. Currently, the major topical treatments have many side effects, making their continued use in patients difficult. Microalgae have emerged as a source of bio-active molecules such as glycolipids with potent anti-inflammatory properties. We aimed to investigate the effects of a glycolipid (MGMG-A) and a glycolipid fraction (MGDG) obtained from the microalga Isochrysis galbana on a TPA-induced epidermal hyperplasia murine model. In a first set of experiments, we examined the preventive effects of MGMG-A and MGDG dissolved in acetone on TPA-induced hyperplasia model in mice. In a second step, we performed…

Keratinocytes0301 basic medicineglycolipidsAdministration Topicalmedicine.medical_treatmentPharmaceutical SciencePharmacologyIsochrysis galbanaOintmentsMGDGMiceDrug DiscoveryMicroalgaelcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)Skinintegumentary systembiologyChemistrymicroalgaeHaptophytaHyperplasiaepidermal hyperplasiaCytokineIsochrysis galbanaCytokinesTetradecanoylphorbol AcetateFemalemedicine.drugskinglycolipids; <b>MGDG</b>; skin; inflammation; epidermal hyperplasia; microalgae; <i>Isochrysis galbana</i>Cell SurvivalDrug CompoundingSkin AbsorptionSkin DiseasesArticle03 medical and health sciencesGlycolipidIn vivoPsoriasismedicineAnimalsHumansDexamethasoneInflammationHyperplasiamedicine.diseasebiology.organism_classificationEpidermal hyperplasia030104 developmental biologylcsh:Biology (General)inflammationGlycolipidsEx vivoMarine Drugs
researchProduct

Increased Susceptibility to Skin Carcinogenesis Associated with a Spontaneous Mouse Mutation in the Palmitoyl Transferase Zdhhc13 Gene

2015

International audience; Here we describe a spontaneous mutation in the Zdhhc13 (zinc finger, DHHC domain containing 13) gene (also called Hip14l), one of 24 genes encoding palmitoyl acyltransferase (PAT) enzymes in the mouse. This mutation (Zdhhc13luc) was identified as a nonsense base substitution, which results in a premature stop codon that generates a truncated form of the ZDHHC13 protein, representing a potential loss-of-function allele. Homozygous Zdhhc13luc/Zdhhc13luc mice developed generalized hypotrichosis, associated with abnormal hair cycle, epidermal and sebaceous gland hyperplasia, hyperkeratosis, and increased epidermal thickness. Increased keratinocyte proliferation and accel…

KeratinocytesPathologySkin NeoplasmsMutantMESH: Codon TerminatorMESH: Epidermal Cellsmedicine.disease_causeBiochemistryMESH: Acyltransferases / genetics*MESH: Keratinocytes / physiologyMice0302 clinical medicineHair cycleMESH: AnimalsPalmitoyl acyltransferase0303 health sciencesintegumentary systemNF-kappa B3. Good healthPhenotypemedicine.anatomical_structureNeutrophil Infiltration030220 oncology & carcinogenesisCodon TerminatorKeratinocytemedicine.medical_specialtyClinical SciencesOncology and CarcinogenesisDermatologyBiologyMESH: PhenotypeMESH: Skin Neoplasms / etiologyArticleMESH: Skin Neoplasms / genetics*03 medical and health sciencesMESH: Genetic Predisposition to Disease*medicineAnimalsGenetic Predisposition to DiseaseTerminatorMESH: NF-kappa B / physiologyCodonMESH: MiceMolecular Biology030304 developmental biologyEpidermis (botany)Dermatology & Venereal DiseasesMESH: Leukocyte Elastase / metabolismCell BiologyMESH: Bromodeoxyuridine / metabolismNFKB1Molecular biologyMESH: Neutrophil Infiltration[SDV.GEN.GA]Life Sciences [q-bio]/Genetics/Animal geneticsBromodeoxyuridineEpidermal CellsMutationNIH 3T3 CellsMESH: Mutation*Leukocyte ElastaseCarcinogenesisDHHC domainAcyltransferasesMESH: NIH 3T3 CellsJournal of Investigative Dermatology
researchProduct

Biomimetic Alginate/Gelatin Cross-Linked Hydrogels Supplemented with Polyphosphate for Wound Healing Applications

2020

In the present study, the fabrication of a biomimetic wound dressing that mimics the extracellular matrix, consisting of a hydrogel matrix composed of non-oxidized and periodate-oxidized marine alginate, was prepared to which gelatin was bound via Schiff base formation. Into this alginate/oxidized-alginate-gelatin hydrogel, polyP was stably but reversibly integrated by ionic cross-linking with Zn2+ ions. Thereby, a soft hybrid material is obtained, consisting of a more rigid alginate scaffold and porous structures formed by the oxidized-alginate-gelatin hydrogel with ionically cross-linked polyP. Two forms of the Zn-polyP-containing matrices were obtained based on the property of polyP to f…

Keratinocyteszinc ionscell migrationMetal NanoparticlesPharmaceutical ScienceBiocompatible Materials02 engineering and technologyGelatinAnalytical ChemistryExtracellular matrixchemistry.chemical_compoundBiomimeticsCell MovementPolyphosphatesSpectroscopy Fourier Transform InfraredDrug DiscoveryalginateSkinchemistry.chemical_classificationcoacervate0303 health sciencesCoacervateTissue ScaffoldsHydrogelsPolymerHydrogen-Ion Concentration021001 nanoscience & nanotechnologyExtracellular MatrixZincChemistry (miscellaneous)Self-healing hydrogelsMolecular Medicine0210 nano-technologyHybrid materialPorosityinorganic polyphosphatefood.ingredientionic cross-linkingAlginatesCell Survivalperiodate oxidationArticlegelatinlcsh:QD241-44103 medical and health sciencesfoodlcsh:Organic chemistryHumansPhysical and Theoretical Chemistry030304 developmental biologyIonsWound HealingTissue EngineeringPolyphosphateOrganic Chemistryhuman epidermal keratinocytestechnology industry and agricultureChemical engineeringchemistrynanoparticlesEpidermisWound healingMolecules
researchProduct

Multisciplinary management of patients with liver metastasis from colorectal cancer

2016

Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to res…

Liver metastase0301 basic medicinemedicine.medical_specialtyChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor; Epidermal Growth Factor; GastroenterologyColorectal cancermedicine.medical_treatmentAngiogenesis InhibitorsColorectal NeoplasmReviewChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor Epidermal Growth Factor; GastroenterologyMetastasis03 medical and health sciencesLiver metastases0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCombined Modality TherapyChemotherapyHepatectomyHumansDisease management (health)ChemotherapyAntineoplastic Combined Chemotherapy ProtocolLiver resectionEpidermal Growth Factorbusiness.industryGeneral surgeryHepatobiliary diseaseLiver NeoplasmsGastroenterologyDisease ManagementGeneral MedicineMultidisciplinary teammedicine.diseaseColorectal cancerCombined Modality TherapyRadiation therapyErbB Receptors030104 developmental biologyLiver Neoplasm030220 oncology & carcinogenesisReceptor Epidermal Growth FactorHuman medicineHepatectomybusinessColorectal NeoplasmsAngiogenesis InhibitorHumanReceptor
researchProduct

Use of intravenous immunoglobulins in Lyell syndrome: Experience of three cases

1996

We present our experience of treatment of the last three cases of Lyell syndrome we have observed. They are three female children, aged between 16 months and 3 years, who showed many features in common with severely burnt patients (large exuding lesions, severe reduction of circulating plasmatic volume, large denuded body surfaces, severe tendency to infections, ...). Therefore, together with the already known scheme of treatment (corticosteroids, correction of hydroelectrolitic balance, antimicrobials), we decided to use intravenous Immunoglobulins (IVIG), which had been already positively used in severely burnt patients. The favorable evolution of the affection in all three cases and the …

Lyell syndromeIntravenous Immunoglobulines (IVIG)Toxic Epidermal Necrolysis (TEN)
researchProduct

Oculoectodermal syndrome: Report of a new case with a broad clinical spectrum

2014

Oculoectodermal syndrome (OMIM 600268) is rare and characterized by aplasia cutis congenita, epibulbar dermoids, and other abnormalities. We report herein on a newly recognized patient with oculoectodermal syndrome, which is the 19th reported patient with OES. The boy aged six years demonstrated a broad clinical spectrum of this condition, including aplasia cutis congenita, epibulbar dermoids, hyperkeratotic papule, mildly enlarged cisterna magna, and an enlarged fluid space in the quadrigeminal cistern, suggesting a cyst. He also manifested anomalies not reported associated with this disorder, including systematized epidermal nevus following Blaschko's lines, hypopigmented skin lesions, an…

Malemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAplasia cutis congenitaHypopigmented skin lesionsEctodermal DysplasiaOculoectodermal syndromeGeneticsmedicineHumansCystGenetics (clinical)Dermoid CystSkinHyperkeratotic papuleHypopigmentationSystematized epidermal nevusbusiness.industryEpibulbar dermoidsBrainmedicine.diseaseMagnetic Resonance ImagingDermatologyEnlarged cisterna magnaPhenotypeChild Preschoolmedicine.symptombusinessAmerican Journal of Medical Genetics Part A
researchProduct

Accuracy of SCORTEN to predict the prognosis of Stevens‐Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta‐analysis

2019

BACKGROUND The SCORTEN score is a specific predictor of the probability of death for patients diagnosed with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). OBJECTIVES To evaluate the overall accuracy of SCORTEN and the influence of several moderators such as age, sex, geographical region and age of the study. METHODS A systematic search was performed on MEDLINE, The Cochrane Library, EMBASE, SCOPUS and Web of Knowledge, with no restriction on language (last update 5 February 2019 for all databases). Original studies on the use of SCORTEN were eligible. The standardized mortality ratio (SMR), defined as the quotient between the number of deaths observed and the number expec…

Multivariate statisticsmedicine.medical_specialtyBody Surface AreaMEDLINEDermatologyDiseaseCochrane LibrarySeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRetrospective StudiesBody surface areabusiness.industry030208 emergency & critical care medicinePrognosismedicine.diseaseToxic epidermal necrolysisInfectious DiseasesStandardized mortality ratioStevens-Johnson SyndromeMeta-analysisbusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast canc…

2021

Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers. The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with th…

OncologyCPS combined positive scoreTC tumor cellsICI immune checkpoint inhibitorTriple Negative Breast NeoplasmsB7-H1 AntigenMedicineHER2 human epidermal growth factor receptor 2Triple-negative breast cancerRC254-282ICC intraclass correlation coefficientbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMSI microsatellite instabilityImmunohistochemistrypCR pathological complete responsePFS progression-free survivalImmunohistochemistryOriginal ArticleIC-ScoreIC immune cellsIHC immunohistochemistryProgrammed deathPD-L1medicine.medical_specialtyConcordanceTNBC triple-negative breast cancerOS overall survivalBreast cancerTriple-negative breast cancerPD-L1Internal medicineTPS tumor proportion scoreBiomarkers TumorHumansProgrammed death-ligand 1Reproducibilitybusiness.industryReproducibility of Resultsmedicine.diseaseITT intention to treatCI confidence intervalPD-L1 programmed death-ligand 1biology.proteinSurgeryCPSbusinessKappaTMB tumor mutational burdenBreast
researchProduct

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

2013

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. &lt;b&gt;&lt;i&gt;Patients and Methods:&lt;/i&gt;&lt;/b&gt; Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). &lt;b&gt;&lt;i&gt;Results:&lt;…

OncologyCancer Researchmedicine.medical_specialtyAnthracyclineSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentPopulationAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedVentricular Function LeftBreast cancer; Elderly patients; Human epidermal growth factor receptor type 2; TrastuzumabBreast cancerBreast cancerTrastuzumabInternal medicinemedicineHumansAdverse effecteducationGeriatric AssessmentAgedRetrospective StudiesAged 80 and overChemotherapyCardiotoxicityeducation.field_of_studybusiness.industryRetrospective cohort studyGeneral MedicineTrastuzumabmedicine.diseaseHuman epidermal growth factor receptor type 2OncologyFemalebusinessElderly patientmedicine.drugOncology
researchProduct